MedTrace Logo

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency

NCT00745316 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2023-09-11

No results posted yet for this study

Summary

The main purpose of this study is to determine the safety and tolerability of tonapofylline (BG9928) when given at different doses to patients with heart failure and renal insufficiency.

This study will also explore:

* Disease related quality-of-life
* Exercise capacity
* Renal function
* Concomitant medications

Conditions

Interventions

DRUG

Tonapofylline

Oral Tonapofylline - 2 capsules bid

DRUG

Placebo

Oral placebo - 2 capsules bid

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00745316 on ClinicalTrials.gov